



(11) **EP 1 895 984 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/14 *(2006.01)* **A61K 31/506** *(2006.01)*

(86) International application number:
PCT/US2006/021657

(48) Corrigendum issued on:
12.05.2010 Bulletin 2010/19

(87) International publication number:
WO 2006/133046 (14.12.2006 Gazette 2006/50)

(45) Date of publication and mention
of the grant of the patent:
03.03.2010 Bulletin 2010/09

(21) Application number: **06772091.2**

(22) Date of filing: **05.06.2006**

(54) **NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS**
NANOTEILCHENFÖRMIGE IMATINIB-MESYLAT-FORMULIERUNGEN
FORMULATIONS D'IMATINIB MESYLATE NANOPARTICULAIRES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: **03.06.2005 US 687146 P**

(43) Date of publication of application:
12.03.2008 Bulletin 2008/11

(73) Proprietor: **Elan Pharma International Limited**
County Westmeath (IE)

(72) Inventors:
• **JENKINS, Scott**
Downingtown, PA 19335 (US)
• **LIVERSIDGE, Gary, G.**
Westchester, PA 19380 (US)

(74) Representative: **Pohlman, Sandra M.**
df-mp
Fünf Höfe
Theatinerstrasse 16
80333 München (DE)

(56) References cited:
WO-A-2006/054314 WO-A-2006/110811
US-A1- 2005 042 177

EP 1 895 984 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).